Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

HIV Infection

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 104 articles: HTML format Text format

Single Articles

January 2012
1. CROTEAU D , Letendre S, Best BM, Rossi SS, et al
   THERAPEUTIC AMPRENAVIR CONCENTRATIONS IN CEREBROSPINAL FLUID.
   Antimicrob Agents Chemother. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. ORDONEZ P , Hamasaki T, Isono Y, Sakakibara N, et al
   Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.
   Antimicrob Agents Chemother. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. CLOUSER CL , Holtz CM, Mullett M, Crankshaw DL, et al
   Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1.
   Antimicrob Agents Chemother. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. SMYTHE W , Khandelwal A, Merle C, Rustomjee R, et al
   A semi-mechanistic pharmacokinetic-enzyme turn-over model for rifampicin autoinduction in adult tuberculosis patients.
   Antimicrob Agents Chemother. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. ANANWORANICH J , Gorowara M, Avihingsanon A, Kerr SJ, et al
   Pharmacokinetic and short-term virologic response of low dose raltegravir 400mg once daily maintenance therapy.
   Antimicrob Agents Chemother. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. HENRICH TJ , Lewine NR, Lee SH, Rao SS, et al
   Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small Molecule CCR5 Antagonists.
   Antimicrob Agents Chemother. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. KIRBY KA , Marchand B, Ong YT, Ndongwe TP, et al
   Structural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse Transcriptase.
   Antimicrob Agents Chemother. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. STODDART CA , Nault G, Galkina SA, Bousquet-Gagnon N, et al
   Preexposure Prophylaxis with Albumin-Conjugated C34 Peptide HIV-1 Fusion Inhibitor in SCID-hu Thy/Liv Mice.
   Antimicrob Agents Chemother. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
9. SOHL CD , Singh K, Kasiviswanathan R, Copeland WC, et al
   The Mechanism of Interaction of Human Mitochondrial DNA Polymerase gamma with the Novel Nucleoside Reverse Transcriptase Inhibitor 4' -Ethynyl-2-Fluoro-2' -Deoxyadenosine Indicates a Low Potential for Host Toxicity.
   Antimicrob Agents Chemother. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. JOHNSON TJ , Srinivasan P, Albright TH, Watson-Buckheit K, et al
    Safe and Sustained Vaginal Delivery of Pyrimidinedione HIV-1 Inhibitors from Polyurethane Intravaginal Rings.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. GONZALEZ-SERNA A , McGovern RA, Harrigan PR, Vidal F, et al
    Correlation of the virological response to short-term Maraviroc monotherapy with standard and deep sequencing-based genotypic tropism methods.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2011
12. VOURVAHIS M , Langdon G, Labadie RR, Layton G, et al
    Pharmacokinetic Effects of Co-Administration of Lersivirine with Raltegravir or Maraviroc in Healthy Subjects.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. SCHADER SM , Oliveira M, Ibanescu RI, Moisi D, et al
    The In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. BENABOUD S , Hirt D, Launay O, Pannier E, et al
    Pregnancy-Related effects on Tenofovir Pharmacokinetics: A Population Study with 186 women.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. MOSS JA , Malone AM, Smith TJ, Kennedy S, et al
    Simultaneous Delivery of Tenofovir and Acyclovir via an Intravaginal Ring.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. PORTER KA , Cole SR, Eron JJ Jr, Zheng Y, et al
    HIV-1 protease inhibitors and clinical malaria: A secondary analysis of ACTG A5208.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. BENABOUD S , Treluyer JM, Urien S, Blanche S, et al
    Pregnancy related effects on Lamivudine Pharmacokinetics: a Population Study with 228 women.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. ELSE LJ , Douglas M, Dickinson L, Back DJ, et al
    Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. HENDERSON GJ , Lee SK, Irlbeck DM, Harris J, et al
    Interplay Between Single Resistance-Associated Mutations in the HIV-1 Protease and Viral Infectivity, Protease Activity, and Inhibitor Sensitivity.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. MCFADDEN K , Fletcher P, Rossi F, Kantharaju, et al
    Antiviral Breadth and Combination Potential of Peptide Triazole HIV-1 Entry Inhibitors.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. AVILOV SV , Boudier C, Gottikh M, Darlix JL, et al
    Characterization of the inhibition mechanism of the HIV-1 nucleocapsid protein chaperone activities by methylated oligoribonucleotides.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. SELHORST P , Grupping K, Bourlet T, Delezay O, et al
    IN VITRO ACTIVITY OF CANDIDATE MICROBICIDES AGAINST CELL-ASSOCIATED HIV.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. CHAMOUN AM , Chockalingam K, Bobardt M, Simeon R, et al
    PD 404,182 is a virucidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. VISSEAUX B , Charpentier C, Hurtado-Nedelec M, Storto A, et al
    In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. ST-PIERRE C , Ouellet M, Giguere D, Ohtake R, et al
    Galectin-1 specific inhibitors as a new class of compounds to treat HIV-1 infection.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. FERNANDEZ-ROMERO JA , Abraham CJ, Rodriguez A, Kizima L, et al
    Zinc Acetate/Carrageenan Gels Exhibit Potent Activity In Vivo Against High Dose HSV-2 Vaginal and Rectal Challenge.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. SCHOPMAN NC , Braun A, Berkhout B
    Directed HIV-1 evolution of protease inhibitor resistance by 2nd generation short hairpin RNAs.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
28. JOHNSON BC , Metifiot M, Pommier Y, Hughes SH, et al
    Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. LU X , Liu L, Zhang X, Lau TC, et al
    F18, a novel small molecule NNRTI, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. NUTTALL J , Kashuba A, Wang R, White N, et al
    The Pharmacokinetics of Tenofovir Following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. THEE S , Seddon JA, Donald PR, Seifar HI, et al
    PHARMACOKINETICS OF ISONIAZID, RIFAMPICIN AND PYRAZINAMIDE IN CHILDREN YOUNGER THAN TWO YEARS OF AGE WITH TUBERCULOSIS; EVIDENCE FOR IMPLEMENTATION OF REVISED WORLD HEALTH ORGANIZATION RECOMMENDATIONS.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
32. KREDO T , Mauff K, Van der Walt JS, Wiesner L, et al
    The interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1 infected patients.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. FRANK M , von Kleist M, Kunz A, Harms G, et al
    Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: A combined pharmacokinetic, pharmaco- and viral dynamic analysis to predict clinical outcomes.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. HONG Y , Kowalski KG, Zhang J, Zhu L, et al
    Model-based Approach for Optimization of Atazanavir Dose Recommendations for HIV-infected Pediatric Patients.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. MAGEE WC , Valiaeva N, Beadle JR, Richman DD, et al
    Inhibition of HIV-1 by Octadecyloxyethyl Esters of (S)-[3- Hydroxy-2-(phosphonomethoxy)propyl] Nucleosides and Evaluation of Their Mechanism of Action.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. BAHETI G , Kiser JJ, Havens PL, Fletcher CV, et al
    Plasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1 Infected Patients.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. SANCHEZ A , Cabrera S, Santos D, Valverde MP, et al
    POPULATION PHARMACOKINETIC/PHARMACOGENETIC MODEL IN CAUCASIAN HIV-INFECTED PATIENTS FOR OPTIMIZATION OF EFAVIRENZ THERAPY.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. FLYNN PM , Mirochnick M, Shapiro DE, Bardeguez A, et al
    Pharmacokinetics and Safety of Single Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1 Infected Pregnant Women and their Infants.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. WATSON-BUCKHEIT K , Yang L, Buckheit RW Jr
    Development of Dual-Acting Pyrimidinediones as Novel and Highly Potent Topical Anti-HIV Microbicides.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. DUVAL M , Lewis CJ, Nomellini JF, Horwitz MS, et al
    Enhanced neutralization of HIV by antibodies displayed on the S-layer of Caulobacter crescentus.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. DIERYNCK I , Van Marck H, Van Ginderen M, Jonckers TH, et al
    TMC310911, a Novel Human Immunodeficiency Virus Type-1 Protease Inhibitor shows in Vitro an Improved Resistance Profile and Higher Genetic Barrier to Resistance Compared with Current Protease Inhibitors.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
42. METIFIOT M , Johnson B, Smith S, Zhao XZ, et al
    MK-0536 inhibits HIV-1 integrases resistant to raltegravir.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. NSANZABANA C , Rosenthal PJ
    In vitro activity against Plasmodium falciparum of antiretroviral drugs.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. WEIDLE PJ , Zeh C, Martin A, Lando R, et al
    Nelfinavir and its active metabolite, hydroxyl-t-butylamidenelfinavir (M8), are transferred in low quantities to breast milk and do not result in biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. MONNO L , Saracino A, Scudeller L, Punzi G, et al
    Impact of mutations outside the V3 region on co-receptor tropism phenotypically assessed in subtype B HIV-1 infected patients.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. KIM S , Kim YC, Qi H, Su K, et al
    Efficient Identification of Human Immunodeficiency Virus Type 1 Mutants Resistant to a Protease Inhibitor Using a Random Mutant Library.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. STURMER M , Stephan C, Gute P, Knecht G, et al
    Comparison of Drug Resistance Scores for Tipranavir in PI-naive HIV-1 Infected Patients with B and Non-B Subtypes.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. HIGHTOWER KE , Wang R, Deanda F, Johns BA, et al
    Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. RUIZ-MATEOS E , Gonzalez-Serna A, Genebat M, Machmach K, et al
    Virological response after a short-term CCR5 antagonist exposure in HIV-infected patients: Frequency of subjects with virological response and associated factors.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
50. THEE S , Seifart HI, Rosenkranz B, Hesseling AC, et al
    Pharmacokinetics of Ethionamide in Children.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. DE LASTOURS V , Fonsart J, Burlacu R, Gourmel B, et al
    Concentrations of Tenofovir and Emtricitabine in Saliva: Implications for Pre-exposure Prophylaxis of Oral HIV Acquisition.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. MOON SM , Kim T, Sung H, Kim MN, et al
    Outcomes of Moderate-to-Severe Pneumocystis Pneumonia Treated with Adjunctive Steroid in Non-HIV-Infected Patients.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. DUNN DT , Goodall RL, Munderi P, Cityo C, et al
    Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. FARIAS RV , Vargas DA, Castillo AE, Valenzuela B, et al
    Expression of an Mg2+-dependent HIV-1 RNase H construct for drug screening.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. WANG L , Soon GH, Seng KY, Li J, et al
    Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy Volunteers.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. FOISSAC F , Urien S, Hirt D, Frange P, et al
    Pharmacokinetics and virological efficacy after switch to once-daily lopinavir/r in treatment-experienced HIV-1 infected children.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
57. URANO E , Kuramochi N, Ichikawa R, Yamagata Murayama S, et al
    A Novel Postentry Inhibitor of Human Immunodeficiency Virus Type 1 Replication Screened by Yeast Membrane-associated Two-hybrid System.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
58. JAIN A , Lal N, Kumar L, Verma V, et al
    Novel trichomonacidal spermicides.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. BOFFITO M , Jackson A, Amara A, Back D, et al
    Pharmacokinetics of darunavir/ritonavir and atazanavir/ritonavir once daily over 72 hours following drug cessation.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
60. JONSSON S , Davidse A, Wilkins J, Van der Walt JS, et al
    Population pharmacokinetics of ethambutol in South African tuberculosis patients.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. KING JR , Yogev R, Jean-Philippe P, Graham B, et al
    Steady-State Pharmacokinetics of Tenofovir Based Regimens in HIV-Infected Pediatric Patients.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
62. METEER JD , Koontz D, Asif G, Zhang HW, et al
    The Base Component of 3' -Azido-2' ,3' -Dideoxynucleosides Influences Resistance Mutations Selected in HIV-1 Reverse Transcriptase.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
63. WEBER J , Vazquez AC, Winner D, Rose JD, et al
    A Novel Method for the Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3' Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: A Useful Tool in the Multi-Target Era
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. MARSDEN MD , Avancena P, Kitchen CM, Hubbard T, et al
    Single Mutations in HIV Integrase Confer High-Level Resistance to Raltegravir in Primary Human Macrophages.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. MEHTA SD , Maclean I, Ndinya-Achola JO, Moses S, et al
    Emergence of Quinolone-Resistance and Cephalosporin MIC Creep in Neisseria gonorrhoeae in a Cohort of Young Men in Kisumu, Kenya: 2002 - 2009.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
66. GOLDWIRT L , Braun J, de Castro N, Charreau I, et al
    Switch from Enfuvirtide to Raltegravir Lowers Plasma Concentrations of Darunavir and Tipranavir: a pharmacokinetic sub-study of the EASIER-ANRS 138 trial.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
67. BAZZOLI C , Benech H, Rey E, Retout S, et al
    Population joint pharmacokinetic analysis of zidovudine, lamivudine and their active intracellular metabolites in HIV patients.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. REIGADAS S , Masquelier B, Calmels C, Laguerre M, et al
    Structure analysis of HIV-1 IN Y143C/R Raltegravir resistance mutation in association with the secondary mutation T97A.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
69. DECLOEDT EH , McIlleron H, Smith P, Merry C, et al
    The pharmacokinetics of lopinavir in HIV-infected adults receiving rifampicin with adjusted doses of lopinavir/ritonavir tablets.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles   
    
    
    
    April 2011
70. LU W , Salzwedel K, Wang D, Chakravarty S, et al
    A Single Polymorphism in HIV-1 Subtype C SP1 is Sufficient to Confer Natural Resistance to the Maturation Inhibitor, Bevirimat.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
71. MARIER JF , Trinh M, Pheng LH, Palleja SM, et al
    Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-Experienced and CCR5 Antagonist-Naive Patients.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
72. LI Y , Qin L, Peng N, Liu G, et al
    The Antimalarial Effect of Human Immunodeficiency Virus Protease Inhibitors in Rhesus Macaques.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
73. LANSDON EB , Liu Q, Leavitt SA, Balakrishnan M, et al
    Structural and Binding Analysis of Pyrimidinol Carboxylic Acid and N-hydroxy Quinazolinedione HIV-1 RNase H Inhibitors.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. GUPTA S , Vingerhoets J, Fransen S, Tambuyzer L, et al
    Connection Domain Mutations in HIV-1 Reverse Transcriptase do not Impact Etravirine Susceptibility and Virologic Responses to Etravirine-containing Regimens.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
75. HIRT D , Ekouevi DK, Pruvost A, Urien S, et al
    Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 - Step 2).
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
76. SALIOU A , Delobel P, Dubois M, Nicot F, et al
    Concordance Between Two Phenotypic Assays and Ultra Deep Pyrosequencing for Determining HIV-1 Tropism.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
77. HIRT D , Pruvost A, Ekouevi DK, Urien S, et al
    Very high active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 - Step 2).
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
78. TRABOULSI RS , Mukherjee PK, Chandra J, Salata RA, et al
    Gentian Violet Exhibits Activity against Biofilms formed by Oral Candida isolates Obtained from HIV-infected Patients.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
79. GOVENDER NP , Patel J, van Wyk M, Chiller TM, et al
    Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Obtained Through Population-based Surveillance, South Africa, 2002-2003 and 2007-2008.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
80. WANG L , Sun R, Eriksson S
    The Kinetic Effects on Thymidine Kinase 2 by Enzyme Bound dTTP May Explain Mitochondrial Side Effects of Antiviral Thymidine Analogs.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
81. CLAVEL C , Peytavin G, Tubiana R, Soulie C, et al
    Raltegravir Concentrations in the Genital Tract of HIV-1 infected Women Treated with a raltegravir containing Regimen : DIVA 01 study.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
82. LAM AM , Espiritu C, Murakami E, Zennou V, et al
    Inhibition of Hepatitis C Virus Replicon RNA Synthesis by PSI-352938, a Cyclic Phosphate Prodrug of {beta}-D-2'-Deoxy-2'-{alpha}-Fluoro-2'-{beta}-C-Methylguanosine.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
83. DICKINSON L , Boffito M, Back D, Else L, et al
    Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
84. ARMSTRONG KL , Lee TH, Essex M
    The Replicative Fitness Costs of Non-Nucleoside Reverse Transcriptase Inhibitor Drug Resistance Mutations on HIV Subtype C.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
85. SIMIELE M , D'Avolio A, Baietto L, Siccardi M, et al
    Evaluation of mean corpuscular volume of HIV patients PBMCs by a Coulter counter to determine intracellular drugs concentrations.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
86. GANTT S , Carlsson J, Ikoma M, Gachelet E, et al
    The HIV protease inhibitor nelfinavir inhibits Kaposi sarcoma-associated herpesvirus replication in vitro.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
87. SCARTH BJ , White KL, Chen JM, Lansdon EB, et al
    Mechanism of resistance to GS-9148 by the Q151L mutation in HIV-1 Reverse Transcriptase.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
88. VERRET WJ , Arinaitwe E, Wanzira H, Bigira V, et al
    Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malaria.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
89. SCHINAZI RF , Massud I, Rapp KL, Cristiano M, et al
    Selection and characterization of HIV-1 with a novel S68 deletion in the reverse transcriptase.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
90. SEEGULAM ME , Ratner L
    Integrase Inhibitors Effective Against Human T-Cell Leukemia Virus Type 1.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
91. PIRRONE V , Thakkar-Rivera N, Jacobson JM, Wigdahl B, et al
    Combinatorial Approaches to the Prevention and Treatment of HIV-1 Infection.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
92. VU BC , Boyer PL, Siddiqui MA, Marquez VE, et al
    4'C-methyl-2'-deoxyadenosine and 4'C-ethyl-2'-deoxyadeonosine Inhibit HIV-1 Replication.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
93. SASSI AB , Cost MR, Cole AL, Cole AM, et al
    Formulation development of Retrocyclin-1 (RC-101) as an anti-HIV vaginal microbicide product.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
94. CAMPBELL PJ , Morlock GP, Sikes RD, Dalton TL, et al
    Molecular Detection of Mutations Associated with First and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing in M. tuberculosis.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
95. SCHANZER J , Jekle A, Nezu J, Lochner A, et al
    DEVELOPMENT OF TETRAVALENT, BI-SPECIFIC CCR5 ANTIBODIES WITH ANTIVIRAL ACTIVITY AGAINST CCR5 MAB-RESISTANT HIV-1 STRAINS.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
96. DOMINGO P , Cabeza MC, Pruvost A, Torres F, et al
    Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
97. SELHORST P , Vazquez AC, Terrazas-Aranda K, Michiels J, et al
    HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (CROSS-) RESISTANCE TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS CURRENTLY UNDER DEVELOPMENT AS MICROBICIDES.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
98. IDE K , Aoki M, Amano M, Koh Y, et al
    Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
99. LARROUY L , Lambert-Niclot S, Charpentier C, Fourati S, et al
    Positive Impact of HIV-1 Gag Cleavage Site Mutations on Virological Response to Darunavir Boosted with Ritonavir.
    Antimicrob Agents Chemother. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
100. HAWKINS T , Veikley W, Durand-Gasselin L, Babusis D, et al
     Intracellular Nucleotide Levels During Co-Administration of Tenofovir Disoproxil Fumarate and Didanosine in HIV-1 Infected Patients.
     Antimicrob Agents Chemother. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
101. MCCORMICK AL , Parry CM, Crombe A, Goodall RL, et al
     The impact of the N348I mutation in HIV-1 reverse transcriptase, on non-nucleoside reverse transcriptase inhibitor resistance in non subtype B HIV-1.
     Antimicrob Agents Chemother. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
102. CALLEBAUT C , Stray K, Tsai L, Williams M, et al
     In Vitro Characterization of GS-8374, a Novel Phosphonate-Containing Inhibitor of HIV-1 Protease with Favorable Resistance Profile.
     Antimicrob Agents Chemother. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
103. HRUZ PW , Yan Q, Tsai L, Koster J, et al
     GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy rodent model system.
     Antimicrob Agents Chemother. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
104. MAHALINGAM A , Simmons AP, Ugaonkar SR, Watson KM, et al
     Vaginal microbicide gel for the delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1.
     Antimicrob Agents Chemother. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     

Thank you for your interest in scientific medicine.

This service is provided by AMEDEO through an unrestricted educational grant from Boehringer Ingelheim.

Amedeo is a Flying Publisher website.    Design: